Agenus, a US-based biotechnology company headquartered in Lexington, specializes in immuno-oncology therapies targeting cancer and infectious diseases, employing 389 staff. Its pipeline includes advanced antibodies and various immunotherapy classes.
AGEN has been in the news recently: Zydus Lifesciences Ltd. will acquire Agenus Inc.'s biologics facilities for $75 million, which will enhance its capabilities in the global biologics contract development and manufacturing organization (CDMO) market. Additionally, Zynext Ventures invested in Agenus Inc. to support its BOT/BAL program, which has shown promise in treating various cancer types.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
